Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of VNRX-5133 with VNRX-5022 in Renal Impairment
NCT03690362Phase 1Completed
- Sponsor
- Venatorx Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of taniborbactam in bacterial infection (5 arms), sponsored by Venatorx Pharmaceuticals. Primary endpoints: Peak Plasma Concentration at 72 hours, Area under the plasma concentration versus time curve at 72 hours and 1 more. Started Apr 2018; status: completed.
02
Drugs
taniborbactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03690362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690362.